Clinical Scorecard: Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Single-center observational study at The Second Affiliated Hospital of Chongqing Medical University, focusing on patient outcomes.
Key Highlights
High PD-L1 expression is linked to resistance against EGFR-TKIs, impacting treatment choices.
Guideline-Based Recommendations
Diagnosis
Management
Consider immunotherapy options such as pembrolizumab or nivolumab in combination with antiangiogenic drugs for resistant cases.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Noninvasive radiomic analysis can predict PD-L1 levels and guide treatment decisions, while considering potential side effects.
Clinical Best Practices
Implement a multidisciplinary approach involving oncologists, radiologists, and pathologists for managing advanced LUAD.
